February 12, 2021 11:21 AM EST

Ex-Vividion chief Diego Miralles finds 'dream team' at stealthy Flagship portfolio company; Astellas looks inward to select CBO and CSO

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Nicole DeFeudis

Editor

Almost three months after leaving Vividion Therapeutics, where he recently signed a $135 million Roche deal, Diego Miralles has landed the top spot on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex-Vividion chief Diego Miralles finds 'dream team' at stealthy Flagship portfolio company; Astellas looks inward to select CBO and CSO

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Ex-Vi­vid­ion chief Diego Mi­ralles finds 'dream team' at stealthy Flag­ship port­fo­lio com­pa­ny; Astel­las looks in­ward to se­lect CBO and CSO

Copy Chief

Editor

Editor

Sign up to read this article for free.

Ex-Vividion chief Diego Miralles finds 'dream team' at stealthy Flagship portfolio company; Astellas looks inward to select CBO and CSO